Search

A recent study conducted by researchers at Emory University compared the effectiveness of two different treatment regimens for newly diagnosed multiple myeloma (NDMM). The standard-of-care induction therapy, lenalidomide, bortezomib, and dexamethasone (RVd), was compared to a newer regimen that included the addition of daratumumab (Dara-RVd). The study found that the Dara-RVd regimen resulted in improved depth of response and long-term survival benefits compared to RVd alone. The researchers concluded that this analysis demonstrates the utility of the Dara-RVd regimen in real-world clinical practice and provides insights into its performance in patient subsets often underrepresented in clinical trials. [Extracted from the article]

A study conducted at University Hospital in Nantes, France, explored the feasibility of an intensive treatment strategy for high-risk newly diagnosed multiple myeloma (NDMM) patients. The study involved 50 patients who received daratumumab-carfilzomib-lenalidomide-dexamethasone (D-KRd) induction, autologous stem cell transplantation (ASCT), D-KRd consolidation, second ASCT, and daratumumab-lenalidomide maintenance. The primary endpoint of feasibility was met, with 36 patients completing the second transplant. The overall response rate was 100%, and the 30-month progression-free survival and overall survival rates were 80% and 91%, respectively. The study concluded that D-KRd with tandem transplant is feasible and resulted in high response rates and progression-free survival. [Extracted from the article]

A study conducted at Tan Tock Seng Hospital in Singapore has reported on a case of a patient with anti-melanoma differentiation-associated 5 gene autoantibody (anti-MDA5) positive dermatomyositis (DM) with rapidly progressive interstitial lung disease (RP-ILD). This form of autoimmune myositis is difficult to treat and has low survival rates. The patient initially received intensive combination therapy but eventually responded to intravenous daratumumab, an anti-CD38 monoclonal antibody. The use of daratumumab led to clinical and biochemical improvement in the patient. This case suggests that daratumumab may be a potential treatment option for refractory autoimmune conditions. [Extracted from the article]

A recent report discusses research on multiple myeloma conducted by the Dana-Farber Cancer Institute. The study focuses on the use of a treatment regimen called D-RVD, which consists of daratumumab, bortezomib, lenalidomide, and dexamethasone. The research found that D-RVD showed high rates of minimal residual disease (MRD) negativity in newly-diagnosed multiple myeloma patients and is now considered a standard regimen for transplant-eligible patients. The study also examined the activity and safety of D-RVD in patients with high-risk smoldering multiple myeloma (HR-SMM) and found significant activity, including a 100% overall response rate and high rates of MRD-negative disease. [Extracted from the article]

A report from Evangelismos General Hospital in Athens, Greece discusses the findings of a phase 2 study on the treatment of relapsed/refractory multiple myeloma (RRMM) using the oral proteasome inhibitor ixazomib combined with daratumumab and dexamethasone. The study included 61 RRMM patients who received the treatment until disease progression or unacceptable toxicity. The overall response rate was 64.4%, with a confirmed very good partial response rate of 30.5%. The treatment showed a positive risk-benefit profile and was active in clinically relevant subgroups, with no new safety signals. [Extracted from the article]

A recent study conducted by researchers at Catholic University Louvain (UCLouvain) in Brussels, Belgium, highlights the successful treatment of acquired von Willebrand syndrome (AvWS) in a patient with smoldering multiple myeloma. AvWS is a rare condition with approximately 700 cases reported in the literature, and it is often associated with lymphoproliferative, myeloproliferative syndromes, and cardiac diseases. The management of AvWS aims to prevent and treat bleeds and address the underlying pathology. In this case, the patient was treated with daratumumab, lenalidomide, and dexamethasone, which proved to be a rapid and effective treatment for severe AvWS and multiple bleeding complications. [Extracted from the article]

A recent study conducted at the University Hospital Salamanca evaluated the efficacy and safety of selinexor in combination with daratumumab-bortezomib-dexamethasone (DVd) for the treatment of relapsed and refractory multiple myeloma (RRMM). The study enrolled 57 patients, with part 1 including heavily pretreated patients and part 2 including early relapse patients. The overall response rate (ORR) in part 1 was 50% with a median progression-free survival (PFS) of 7 months, while in part 2, the ORR was 82% with a median PFS of 24 months. The most common adverse events were thrombocytopenia and nausea. Although the primary endpoint was not met, the combination of selinexor and DVd showed promising clinical efficacy and a manageable safety profile for RRMM patients. [Extracted from the article]

A new report discusses research findings on multiple myeloma from the Institute of Hematology and Blood Diseases Hospital. The study evaluated the efficacy and safety of subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma. The results showed that subcutaneous daratumumab had a favorable benefit/risk profile, with low incidences of infusion-related reactions and injection-site reactions. The overall response rate was 57.1%, indicating the potential impact of subcutaneous daratumumab on the clinical administration of multiple myeloma treatment in this population. [Extracted from the article]

A recent study conducted at the University of Chicago has reported new findings on the treatment of multiple myeloma. The study evaluated the efficacy and safety of a combination therapy without autologous stem cell transplant in newly diagnosed multiple myeloma patients. The results showed a high rate of stringent complete response and/or measurable residual disease negativity, with improved outcomes over time. The study concluded that the treatment was effective and well-tolerated, with no treatment-related deaths. This research provides valuable insights into the management of multiple myeloma. [Extracted from the article]

Johnson & Johnson has released data from the Phase 3 PERSEUS study, which shows that DARZALEX FASPRO-based regimens improve clinical outcomes for patients with newly diagnosed multiple myeloma. The study found that the use of DARZALEX FASPRO in combination with other drugs led to deepening responses and sustained minimal residual disease negativity, resulting in improved progression-free survival. The data from this study, along with data from other studies, support the use of DARZALEX as a standard-of-care treatment for multiple myeloma patients. [Extracted from the article]

A recent study conducted at Bern University Hospital in Switzerland examined the effects of daratumumab, a drug used in the treatment of multiple myeloma, on stem cell mobilization and post-transplant hematologic recovery. The study analyzed a group of 155 multiple myeloma patients who received autologous stem cell transplantation (ASCT) after first-line induction with or without daratumumab. The results showed that patients who received daratumumab had lower success rates in stem cell mobilization, required more rescue plerixafor, and had lower counts of peripheral CD34+ cells and total collected CD34+ cells. Additionally, these patients experienced prolonged recovery times for neutrophils and platelets, and required more erythrocyte transfusions and platelet concentrates. The study suggests that the use of daratumumab during multiple myeloma induction therapy may negatively impact stem cell mobilization and engraftment in the context of ASCT. [Extracted from the article]

A recent study conducted by researchers at the University of Salamanca in Spain focused on multiple myeloma, a type of blood cancer characterized by the accumulation of malignant plasma cells in the bone marrow. The researchers investigated the potential effect of a drug called tinostamustine, an alkylating deacetylase inhibitor, in combination with daratumumab, an anti-CD38 monoclonal antibody. Their findings showed that tinostamustine increased the expression of CD38 and NKG2D ligands in myeloma cells, enhancing the efficacy of daratumumab. The combination of these two drugs demonstrated a higher anti-myeloma effect compared to individual treatments. These results suggest that tinostamustine could be a potential candidate to improve the efficacy of anti-CD38 monoclonal antibodies in multiple myeloma treatment. [Extracted from the article]

A recent report from Cukurova University in Adana, Turkey, discusses a case of multiple myeloma with an unusual cutaneous presentation. The 57-year-old male patient initially experienced back pain and dyspnea, leading to a diagnosis of multiple myeloma. However, the disease recurred with a cutaneous manifestation on the right cheek malar region. The patient was then treated with an innovative therapy called daratumumab + CYBORG, which showed promising results. This case highlights the evolving landscape of multiple myeloma management, particularly in cases with atypical symptoms like cutaneous involvement. [Extracted from the article]

A recent study conducted at Wake Forest University in Charlotte, North Carolina, has provided updated knowledge about multiple myeloma, a type of cancer. The study focused on the health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma who were treated with daratumumab, lenalidomide, bortezomib, and dexamethasone. Patient-reported outcomes were collected using various tools, and improvements in pain symptoms, global health status, fatigue symptoms, and physical functioning were observed with both treatment groups. These findings contribute to the evidence supporting the clinical benefits of this treatment approach. [Extracted from the article]

A recent study from Tan Tock Seng Hospital in Singapore highlights the case of a 30-year-old Chinese man with anti-MDA5 positive dermatomyositis (DM) and rapidly progressive interstitial lung disease (RP-ILD). Despite intensive combination therapy, the patient's condition remained refractory until treatment with intravenous daratumumab, an anti-CD38 monoclonal antibody. Following daratumumab treatment, the patient experienced clinical and biochemical improvement, with negative anti-MDA5 antibodies, normalized ferritin and transaminases, and improved lung function. This case suggests that daratumumab may be a potential treatment option for refractory autoimmune conditions such as DM with RP-ILD. [Extracted from the article]

Researchers at the University of Cantabria in Santander, Spain, have conducted a phase I/IIa study evaluating the use of melphalan flufenamide (melflufen) in combination with dexamethasone and either daratumumab or bortezomib for the treatment of relapsed/refractory multiple myeloma (MM). The study found that melflufen demonstrated clinical benefit in patients with triple-class refractory MM. The most common adverse events were thrombocytopenia and neutropenia, and the overall response rate was 73% in the daratumumab arm and 78% in the bortezomib arm. The researchers concluded that melflufen 30 mg was the recommended dose for future studies in relapsed/refractory MM. [Extracted from the article]

A study conducted at the Catholic University of the Sacred Heart in Rome, Italy, explores the use of daratumumab in the treatment of post-hematopoietic stem cell transplantation autoimmune hemolytic anemia (AIHA). AIHA is a rare complication of stem cell transplantation, and standard treatments have limited success rates. The study reports a successful case of a 68-year-old patient with post-HSCT AIHA who achieved clinical and laboratory responses after treatment with daratumumab. The researchers suggest that daratumumab may be a safe and effective alternative to conventional immunosuppressive therapy for post-HSCT AIHA and recommend further investigation. [Extracted from the article]

A recent study conducted at Kitasato University School of Medicine in Japan has highlighted the need for improved treatment outcomes for frail elderly patients with multiple myeloma (MM). The study emphasizes the importance of assessing these patients in order to provide optimized treatments that preserve their quality of life. The researchers found that daratumumab (DARA) therapy, a globally used treatment, is effective in frail elderly MM patients and offers quality of life benefits. The study calls for the development of tools to accurately assess frailty and establish optimal treatments for this patient population. [Extracted from the article]

A recent report from Hospital Germans Trias i Pujol in Barcelona, Spain, highlights the efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) for patients with relapsed or refractory multiple myeloma (RRMM). The study found that D-Rd significantly prolonged progression-free survival compared to lenalidomide and dexamethasone alone. Additionally, the combination therapy demonstrated an improved overall survival (OS) compared to the control group. The findings suggest that daratumumab-containing regimens may provide an OS benefit for patients with RRMM. [Extracted from the article]

A new report discusses research on lymphoblastic lymphoma, a rare form of lymphoid neoplasm that primarily affects children and teenagers. The report presents a case study of a 19-year-old man with lymphoblastic lymphoma who initially responded well to treatment but later experienced relapse. The patient was then treated with a combination of nelarabine and daratumumab, which resulted in refractoriness and leukemization. The report emphasizes the limited evidence available for later-line treatments and highlights the importance of achieving cures in the first line of treatment. [Extracted from the article]

A recent study conducted by researchers at the Florida Cancer Specialists and Research Institute compared the progression-free survival of two different treatment regimens for transplant-ineligible newly diagnosed multiple myeloma patients. The study found that daratumumab, lenalidomide, and dexamethasone (DRd) had a significantly lower risk of disease progression or death compared to bortezomib, lenalidomide, and dexamethasone (VRd). The study used a multicenter chart review and included patients treated with DRd and a randomly selected population of VRd patients. These findings suggest that DRd may be a more effective first-line treatment option for transplant-ineligible multiple myeloma patients. [Extracted from the article]

This document provides information about a clinical trial involving the use of daratumumab, an immunotherapy drug, in the treatment of very high-risk T-lineage acute lymphoblastic leukemia (T-ALL). The trial will administer daratumumab to adult patients with T-ALL in combination with the national treatment program. The study aims to evaluate the efficacy and safety of daratumumab in this patient population. The trial is not yet recruiting and is estimated to be completed by January 2029. The document also includes eligibility criteria for participants and contact information for the primary investigator. [Extracted from the article]

A recent study conducted at Mayo Clinic in Jacksonville, Florida, examined the use of daratumumab, an anti-CD38 monoclonal antibody, in combination with lenalidomide and dexamethasone (DRd) or pomalidomide and dexamethasone (DPd) for the treatment of relapsed or refractory multiple myeloma. The study included 504 patients who received daratumumab between January 2015 and April 2019. The results showed that there was no significant difference in progression-free survival (PFS) or overall survival (OS) between the DRd and DPd treatment groups in patients with lenalidomide-exposed or lenalidomide-refractory multiple myeloma. The study suggests that combining daratumumab with lenalidomide is an effective treatment option for patients with prior lenalidomide use. [Extracted from the article]

A recent study conducted by Johnson & Johnson has shown that a quadruplet therapy regimen using DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) has significantly improved outcomes for patients with transplant-eligible newly diagnosed multiple myeloma. The study found that this regimen reduced the risk of disease progression or death by 58% compared to the standard treatment. It also increased the depth of response and resulted in higher rates of complete response and minimal residual disease negativity. The safety profile of the new regimen was consistent with known profiles for the drugs used. These findings suggest that the DARZALEX-based quadruplet therapy could become a new standard of care for transplant-eligible multiple myeloma patients. [Extracted from the article]

A phase III trial presented at the 65th American Society of Hematology Annual Meeting and Exposition found that patients with newly diagnosed multiple myeloma (MM) who received daratumumab in addition to the standard care regimen of bortezomib, lenalidomide, and dexamethasone (VRd) had significantly higher rates of survival without disease progression compared to those who received standard care alone. The trial showed that patients who received daratumumab plus VRd had an estimated four-year progression-free survival rate of 84.3% compared to 67.7% among those receiving VRd alone. The study's lead author, Dr. Pieter Sonneveld, stated that the addition of daratumumab had a major clinical significance in terms of patient well-being and remaining disease-free. Daratumumab is a monoclonal antibody that targets a protein overexpressed in MM cells and has previously been approved for use in certain patients. The trial is the first to test its use as part of frontline therapy for newly diagnosed MM. The study was funded by the European Myeloma Network with support from Janssen Pharmaceuticals. [Extracted from the article]

A recent study conducted at Emory University Winship Cancer Institute in Atlanta, Georgia, explored the safety and efficacy of different induction therapies for multiple myeloma patients. The study compared two treatment arms: one using daratumumab, ixazomib, and dexamethasone (DId), and the other using daratumumab, bortezomib, and dexamethasone (DVd) followed by DId. The primary endpoint of the study was the very good partial response rate (VGPR) after eight cycles of induction therapy. The results showed that arm B had a higher VGPR rate and overall response rate (ORR) compared to arm A. The study also found that both treatment arms had a 3-year progression-free survival (PFS) rate of close to 80%. The researchers concluded that non-IMID (immunomodulatory drug) based daratumumab-combination induction therapies, with a transition from bortezomib to ixazomib, could be a viable alternative for patients who cannot tolerate IMIDs or have contraindications to receive them. [Extracted from the article]

A recent study conducted by researchers at Boston University explored the composition and dynamic evolution of the bone marrow microenvironment (BME) in AL amyloidosis during daratumumab-based therapy. AL amyloidosis is a condition caused by clonal B or plasma cells in the bone marrow that produce misfolded immunoglobulin proteins, leading to multi-organ failure. The study used single-cell RNA sequencing to compare the immune ecosystem and BME in AL amyloidosis patients to healthy donors and other plasma cell disorders. The findings revealed unique characteristics of the BME in AL amyloidosis and dynamic changes within the T cell compartment following daratumumab-based therapy. Further research is needed to validate the potential of BME profiling in diagnosing the disease, predicting treatment response, and developing new therapeutic strategies. [Extracted from the article]

A multicenter study conducted in Turkey evaluated the use of daratumumab therapy in patients with relapsed/refractory multiple myeloma (RRMM). The study included 134 patients who received at least two courses of daratumumab between February 2018 and April 2022. The overall response rate after daratumumab therapy was 55.9%, with a very good partial response or better observed in 35.8% of patients. Overall survival and progression-free survival for all patients were 11.6 and 8.0 months, respectively. The study suggests that early initiation of daratumumab therapy may provide an advantage in terms of survival outcomes. [Extracted from the article]

A recent report from National University discusses research on multiple myeloma, the second most common hematologic malignancy. The study focuses on predicting the response to daratumumab-based therapy, a monoclonal antibody used for multiple myeloma treatment. The researchers used single-cell RNA sequencing and machine-learning methods to develop a gene signature that can predict response to therapy and prognosis in multiple myeloma. The study suggests that these gene signatures could be used to improve treatment allocation and enhance risk group delineation. [Extracted from the article]

A study conducted at Seoul National University Bundang Hospital has found that daratumumab, when combined with bortezomib, melphalan, and prednisone (D-VMP), is more effective than bortezomib, melphalan, and prednisone (VMP) alone in treating transplant-ineligible Asian patients with newly diagnosed multiple myeloma (NDMM). The study, called OCTANS, followed patients for over three years and found that D-VMP resulted in a higher rate of very good partial response or better, as well as a higher rate of measurable residual disease negativity. D-VMP also showed a significant improvement in progression-free survival and a longer time to subsequent antimyeloma therapy. The safety profile of D-VMP was consistent with previous analyses, and daratumumab subcutaneous administration was preferred by the majority of patients who switched from intravenous administration. These findings support the use of daratumumab in combination with VMP for transplant-ineligible Asian patients with NDMM. [Extracted from the article]

A study conducted by the Institut Universitaire du Cancer de Toulouse-Oncopole in France examined the effectiveness of isatuximab, a CD38 monoclonal antibody, in patients with relapsed and/or refractory multiple myeloma (RRMM). The study analyzed real-world data from patients who received isatuximab in France under early access programs. The results showed that isatuximab plus pomalidomide and dexamethasone demonstrated a high median progression-free survival (mPFS) of 16.6 months in patients who were naive to daratumumab, a different CD38 monoclonal antibody. The study also found that isatuximab was effective in patients who were refractory to lenalidomide, another treatment option. The safety profile of isatuximab was generally comparable to previous clinical trials. [Extracted from the article]

A study conducted at the University of Texas MD Anderson Cancer Center explored the use of maintenance therapy with daratumumab (dara) in patients with relapsed multiple myeloma (MM) after salvage autologous hematopoietic stem cell transplantation (auto-HCT). The trial aimed to improve progression-free survival (PFS) in these patients. The study enrolled 13 patients, and the results showed that maintenance therapy with dara, with or without pomalidomide (pom), was safe and feasible, with 83% of patients achieving a complete response (CR). The median PFS was 28.5 months. However, the trial was terminated due to poor accrual. [Extracted from the article]

A study conducted at the Fifth Medical Center of Chinese People's Liberation Army (PLA) General Hospital in Beijing, China, evaluated the efficacy and safety of daratumumab as maintenance therapy after autologous hematopoietic stem cell transplantation (ASCT) for newly diagnosed multiple myeloma (NDMM). The study included 15 patients who received daratumumab maintenance therapy between May 2022 and June 2023. The results showed that daratumumab was safe and effective in increasing the rate of stringent complete response and improving renal response in patients with renal injury. The most common adverse events were lymphopenia, infusion-related reactions, and grade 3 pneumonia. The study suggests that a less dose-intense maintenance regimen for the first 8 weeks may reduce the incidence of pneumonia. [Extracted from the article]

A recent study conducted at Shanghai Changzheng Hospital in China compared the effectiveness of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) alone in Chinese patients with relapsed/refractory multiple myeloma (RRMM). The study found that D-Vd prolonged progression-free survival (PFS) and induced deeper and more durable responses compared to Vd alone. The duration of response, measurable residual disease-negativity rate, and overall survival were also improved with D-Vd. The safety profile of D-Vd remained consistent with previous analyses. Additionally, some patients preferred switching from intravenous to subcutaneous administration of daratumumab. These findings support the use of D-Vd as a standard of care for Chinese patients with RRMM who have received one prior line of therapy. [Extracted from the article]

A new study on disease progression in multiple myeloma, a type of cancer, has been conducted. The study focused on the effectiveness of a combination treatment involving the drugs daratumumab, thalidomide, and dexamethasone. The researchers found that this combination was effective in patients with relapsed or refractory multiple myeloma. The study also highlighted the cost-effectiveness of using thalidomide and dexamethasone in combination with daratumumab. The findings of this study provide valuable insights for the treatment of multiple myeloma. [Extracted from the article]

A recent study conducted in Spain examined the real-world treatment patterns and outcomes of transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) patients. The study compared two groups of patients who received different treatment regimens. The results showed that patients treated with daratumumab in combination with other drugs had improved progression-free survival (PFS) indicators compared to other treatment alternatives. The study suggests that daratumumab regimens may be a beneficial choice for frontline TIE-NDMM patients. [Extracted from the article]

A study conducted in Washington, D.C. examined the characteristics and outcomes of veterans who received daratumumab, an anti-CD38 antibody, in combination with other agents for the treatment of multiple myeloma. The study analyzed electronic medical record data from the Veterans Affairs Corporate Data Warehouse and found that daratumumab combinations are increasingly used in the treatment of multiple myeloma in veterans. The study also observed variations in treatment duration and overall survival among different regimens. The findings suggest that daratumumab combinations are effective in treating multiple myeloma in veterans, with different combinations being used more frequently in different age groups. [Extracted from the article]

A recent report from Tri-Service General Hospital in Taipei, Taiwan, highlights the need for more research on treatments for refractory/relapsed multiple myeloma (R/R MM) in elderly patients. The study conducted a systematic review of the literature and identified 13 eligible randomized controlled trials (RCTs) to evaluate treatment efficacy. The combined therapy of daratumumab, lenalidomide, and dexamethasone (DaraLenDex) was found to be the most effective treatment for R/R MM in elderly patients, with a high progression-free survival rate. However, the researchers emphasize the need for more comprehensive RCTs to confirm these findings. [Extracted from the article]

A recent study conducted by the National Cancer Institute (NCI) has found that daratumumab, a monoclonal antibody, shows promise in treating primary effusion lymphoma (PEL), an aggressive non-Hodgkin lymphoma caused by Kaposi sarcoma-associated herpesvirus (KSHV). The researchers discovered that daratumumab induces cell-mediated cytotoxicity (ADCC) in PEL cell lines, particularly those with high levels of CD38 expression. Additionally, the study found that combining daratumumab with other drugs, such as all trans-retinoic acid (ATRA) and pomalidomide (Pom), increased its effectiveness in low-CD38 expressing PEL cell lines. These findings suggest that daratumumab, either alone or in combination with other drugs, could be a potential therapeutic option for PEL. [Extracted from the article]